2 High-Yield Stocks to Buy in October Without Any Hesitation

Medtronic reported nearly 14% revenue growth in fiscal Q1 2027, its fastest growth pace in roughly a decade, supporting the view that its business overhaul has succeeded; its dividend yield is 3.3%. McCormick, yielding more than 4%, posted 1.9% organic sales growth in Q2 2026 and is pursuing Unilever's food business acquisition, which could roughly double sales and lift emerging-market exposure from 25% to more than 40%. The article views both stocks as attractive long-term dividend opportunities, while flagging consumer-food demand pressure and execution risk around McCormick's unclosed deal.

Analysis

MDT’s rerating case depends less on a dividend-screen bid and more on whether growth converts into durable operating leverage. After a multiyear reset, even modest sustained organic growth can drive disproportionate EPS upside through utilization of the existing sales infrastructure; the key confirmation is sequential expansion in operating margin and procedure-driven franchises, not a single high-growth quarter. Over the next 1-3 months, expect limited catalyst support absent earnings/guidance, but over 6-18 months MDT can close part of its valuation discount to higher-growth device peers if management demonstrates that growth is not purchase-price or FX-led.

MKC is a fundamentally different setup: the pending Unilever food transaction introduces execution, financing, and regulatory risk that can dominate the underlying defensive-staples thesis. Scale synergies are likely credible, but the market should discount them heavily until purchase price, leverage, separation costs, and required divestitures are fully disclosed. The second-order risk is that a larger food platform increases exposure to private-label trade-down and retailer bargaining power; the offset is a broader flavor portfolio that could give MKC stronger procurement leverage and cross-selling reach in faster-growing markets.

Consensus may be too quick to treat both names as equivalent yield recoveries. MDT offers a cleaner self-help-to-growth transition and is the better risk-adjusted long; MKC’s yield may be compensating for a binary deal structure rather than signaling simple undervaluation. A failed MKC deal is not necessarily bullish: it would remove synergy optionality while exposing management’s strategic credibility and potentially leave the stock facing renewed questions about standalone volume growth.

Key Decisions for Investors

• Initiate/maintain a 6-12 month long MDT position versus a short XLV hedge rather than an outright defensive-beta bet. Add only after the next earnings report confirms organic growth plus operating-margin expansion; invalidate if FY revenue guidance is cut or margin progression stalls for two consecutive quarters.
• Use a pair trade: long MDT / short SYK or EW at modest size over 3-6 months if MDT continues to trade at a meaningful EV/EBIT discount despite comparable growth. The upside is multiple catch-up; the principal risk is a procedure slowdown or renewed execution issues in Diabetes/China that reopens the discount.
• Keep MKC on watch pending definitive transaction terms; do not underwrite acquisition synergies before leverage, financing mix, and expected closing timetable are independently disclosed. A long MKC is actionable only if pro forma net leverage and integration costs leave clear room for dividend growth without material EPS dilution beyond year one.
• For existing MKC exposure, consider buying 3-6 month downside protection around deal milestones rather than adding common stock. A regulatory remedy, financing repricing, or adverse synergy update could produce a sharper drawdown than underlying staples demand data would imply.